Recent 8-K filings for ACH

• August 17, 2026, 6:42 AM ET other material materiality 0.65 positive item 7.01item 9.01

  Accendra Health scraps ATM program, sells non-core assets for $45M, targets CEO successor by mid-September

  Company will not implement at-the-market equity program; no impact on results or published guidance.

• August 10, 2026, 6:50 AM ET earnings materiality 0.85 negative item 2.02item 7.01item 9.01

  Accendra Health Q2 revenue down 10%, adjusted loss; CEO Pesicka to retire by end of 2026

  Q2 net revenue $613.2M, down 10% YoY from $681.9M; GAAP EPS -$1.16 vs -$1.09.

• August 10, 2026, 6:36 AM ET leadership materiality 0.70 neutral item 5.02item 7.01item 9.01 ◈ executive_change

  Accendra Health CEO Ed Pesicka to retire by end of 2026; board starts successor search

  CEO Edward A. Pesicka to retire by end of 2026; will also step down from board.

• June 25, 2026, 4:15 PM ET debt materiality 0.70 neutral item 8.01item 9.01

  Accendra Health closes exchange offers: 99.9% of 2029 notes and 99.2% of 2030 notes tendered

  Tendered $478.3M of 2029 notes (99.9%) and $548.0M of 2030 notes (99.2%).

• June 15, 2026, 4:15 PM ET debt materiality 0.80 negative item 1.01item 2.03item 8.01item 9.01 ◈ Debt Financings ×4◈ Material Agreements

  Accendra Health exchanges nearly all outstanding notes for new secured notes at 9%-9.75% rates

  Approximately 99.9% of 2029 Notes ($478.3M) and 99.2% of 2030 Notes ($547.9M) tendered and accepted early.

• May 22, 2026, 4:08 PM ET debt materiality 0.70 negative item 7.01item 9.01

  Accendra Health launches exchange offer for 4.5%/6.625% notes; new 9%/9.75% secured notes

  Offer to exchange $478.7M of 4.500% 2029 notes and $552.2M of 6.625% 2030 notes for secured notes.

• May 11, 2026, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization

  Q1 revenue $627.8M (down 6.8% YoY); GAAP loss from cont. ops $6.5M vs $3.8M loss prior year.

• May 11, 2026, 7:59 PM ET debt materiality 0.85 negative item 1.01item 7.01item 9.01 ◈ Material Agreements

  Accendra Health launches $326.25M 9% first lien notes, $300M revolver, and exchange offers for existing notes

  New $326.25M 9.000% Senior Secured First Lien Notes due 2032 and $300M revolver due 2030.

• February 19, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 9.01

  Accendra Health Q4 revenue $709M; GAAP loss narrows to $9.4M; completes P&HS sale

  Revenue from continuing ops $709M (up 2% YoY); full-year revenue $2.76B (+3% YoY).

• January 5, 2026, 6:59 PM ET M&A materiality 0.75 negative item 9.01

  Accendra Health closes P&HS sale for $375M cash; pro forma revenue falls to $2.68B

  Sold P&HS business for $375M cash on Dec 31, 2025; proceeds used to repay $280M current debt.

• December 31, 2025, 6:59 PM ET M&A materiality 0.90 positive item 1.01item 2.01item 2.03item 5.02item 5.03item 7.01item 9.01 ◈ Governance Changes ×2◈ Debt Financings◈ M&A Transactions◈ Material Agreements

  Owens & Minor completes $375M sale of P&HS segment to Platinum Equity; will rename to Accendra Health

  Sale closed for $375M cash, plus 5% retained equity and preserved tax attributes >$150M.

• December 18, 2025, 6:59 PM ET other material materiality 0.60 neutral item 5.02item 7.01item 9.01

  Owens & Minor to rename as Accendra Health; ticker changes to ACH on Jan 2, 2026

  Name change to Accendra Health, Inc. effective Dec 31, 2025; NYSE ticker becomes "ACH" on Jan 2, 2026.

• October 30, 2025, 7:59 PM ET M&A materiality 0.85 positive item 2.02item 7.01item 9.01

  Owens & Minor to sell Products & Healthcare segment; Q3 adjusted EPS $0.25

  Signed definitive agreement to sell Products & Healthcare Services segment, pivoting to pure-play home-based care.

• October 7, 2025, 7:59 PM ET M&A materiality 0.80 positive item 1.01item 7.01item 9.01

  Owens & Minor sells P&HS segment to Platinum Equity for $375M cash + retained equity

  Cash payment of $375 million at closing, subject to customary adjustments for working capital, net debt, and expenses.

• August 11, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 9.01

  Owens & Minor Q2: GAAP loss from continuing ops $83.8M; Products & Healthcare segment classified as discontinued ops

  Revenue from continuing ops $681.9M, up 3% YoY from $660.4M.

• June 6, 2025, 7:59 PM ET debt materiality 0.75 neutral item 2.04 ◈ Debt Financings

  Owens & Minor to redeem $1B in 10% notes due 2030 after Rotech merger termination

  Merger agreement to acquire Rotech terminated effective June 5, 2025.

• June 5, 2025, 7:59 PM ET M&A materiality 0.85 negative item 1.01item 1.02item 8.01item 9.01

  Owens & Minor terminates $80M Rotech acquisition; will redeem $1B notes

  Mutual termination of merger agreement; OMI pays $80M termination fee to Rotech.

• May 8, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Owens & Minor Q1 adj EPS $0.23, revenue $2.63B; reaffirms FY guide, active on P&HS sale

  Adjusted EPS $0.23 vs $0.19 YoY; GAAP net loss $(0.32) per share vs $(0.29).

• April 4, 2025, 7:59 PM ET debt materiality 0.70 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings

  Owens & Minor closes $1B 10% senior secured notes offering to fund Rotech acquisition

  $1,000,000,000 aggregate principal of 10.000% senior secured notes due 2030 issued.

• April 2, 2025, 7:59 PM ET debt materiality 0.70 neutral item 7.01item 9.01

  Owens & Minor upsizes and prices $1B of 10.000% senior secured notes due 2030

  Upsized to $1B aggregate principal at 10.000% interest, maturing April 15, 2030.

• March 26, 2025, 7:59 PM ET debt materiality 0.65 neutral item 7.01item 8.01item 9.01

  Owens & Minor launches $600M senior secured notes offering to finance Rotech acquisition

  Launched $600M senior secured notes due 2030 in a private placement to QIBs and non-U.S. persons.

• February 28, 2025, 6:59 PM ET earnings materiality 0.80 neutral item 2.02item 7.01item 9.01

  Owens & Minor reports Q4 GAAP net loss $296M, adjusted EPS $0.55; exploring sale of P&HS segment

  Q4 GAAP net loss $296M ($3.84 loss per share); adjusted net income $43M ($0.55 EPS).

• February 3, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Owens & Minor: preliminary Q4 net loss ~$300M, $310M goodwill impairment; launches financing for Rotech acquisition

  Q4 prelim rev $2.67-2.70B; net loss $(288-311)M; adj EBITDA $135-140M; adj EPS $0.52-0.55.

• November 4, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Owens & Minor Q3 revenue up 5% to $2.7B; GAAP net loss $0.17/shr; adj EPS $0.42; debt cut $198M

  Consolidated revenue of $2.7B (+5% YoY); GAAP net loss $(13M) or $(0.17)/share.

• October 15, 2024, 7:59 PM ET regulatory materiality 0.60 neutral item 8.01

  Owens & Minor receives FTC Second Request for Rotech acquisition; closing expected H1 2025

  Company and Rotech received FTC Second Request on October 11, 2024, extending HSR Act waiting period.

• August 2, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Owens & Minor Q2 revenue up 4% to $2.7B; adjusted EPS doubles to $0.36; agrees to acquire Rotech

  Revenue $2.67B (+4% YoY); GAAP net loss $32M ($0.42 loss per share) vs. $28M loss last year.

• July 31, 2024, 7:59 PM ET debt materiality 0.60 neutral item 7.01

  Owens & Minor calls all $171.3M of 4.375% Senior Notes due 2024 for redemption

  Full redemption of 4.375% Senior Notes due 2024 on September 16, 2024 at 100% of principal plus accrued interest.

• July 23, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Owens & Minor reports preliminary Q2 GAAP net loss $0.42-0.46/share, adj. EPS $0.32-$0.36; reaffirms FY guidance

  Revenue $2,651-$2,671M; GAAP net loss per share $(0.42)-$(0.46); adjusted EPS $0.32-$0.36.

• July 23, 2024, 7:59 PM ET M&A materiality 0.85 positive item 1.01item 7.01item 9.01

  Owens & Minor to buy Rotech for $1.36B cash; expects ~$0.15 EPS accretion in second year

  Purchase price $1.36B cash; net $1.32B after ~$40M tax benefits; ~6.3x LTM EBITDA ex-synergies.

• June 24, 2024, 7:59 PM ET leadership materiality 0.60 negative item 5.02 ◈ executive_change ×2

  Owens & Minor CFO Bruni resigns at company's request; interim CFO Leon appointed

  Alexander J. Bruni resigned as EVP & CFO effective June 21, 2024, will remain until Sep 5, 2024 for transition.

• May 3, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Owens & Minor Q1 adj EPS $0.19 (4x YoY); revenue $2.61B up 4%

  Adj EPS $0.19 vs $0.05 YoY; GAAP net loss per share $(0.29) vs $(0.32).

• February 20, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Owens & Minor Q4 adjusted EPS $0.69, revenue $2.66B; full year operating cash flow $741M

  Q4 GAAP net income $17.8M vs loss of $58.0M; adjusted net income $53.6M vs $21.7M.

• December 6, 2023, 6:59 PM ET other material materiality 0.70 positive item 7.01item 9.01

  Owens & Minor sets 2028 targets: revenue >$12B, adj. EPS >$3.50, 20%+ CAGR

  2028 revenue target exceeding $12 billion; adjusted EBITDA above $750 million.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.68 · Most common event earnings

9 positive 9 negative 32 neutral

source · ACH on sec.gov